Compare AUGO & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUGO | AMRX |
|---|---|---|
| Founded | 1946 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.0B |
| IPO Year | N/A | N/A |
| Metric | AUGO | AMRX |
|---|---|---|
| Price | $72.76 | $14.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $48.90 | $13.25 |
| AVG Volume (30 Days) | 1.1M | ★ 3.8M |
| Earning Date | 02-26-2026 | 02-27-2026 |
| Dividend Yield | ★ 2.42% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | $771,589,000.00 | ★ $2,934,959,000.00 |
| Revenue This Year | $46.44 | $9.99 |
| Revenue Next Year | $39.06 | $6.48 |
| P/E Ratio | ★ N/A | $902.37 |
| Revenue Growth | ★ 41.07 | 9.50 |
| 52 Week Low | $14.69 | $6.69 |
| 52 Week High | $76.80 | $15.00 |
| Indicator | AUGO | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 66.07 | 66.41 |
| Support Level | $60.00 | $14.36 |
| Resistance Level | $65.99 | $14.99 |
| Average True Range (ATR) | 4.31 | 0.47 |
| MACD | -0.51 | 0.05 |
| Stochastic Oscillator | 76.13 | 70.21 |
Aura Minerals Inc is a mid-tier gold and copper production company focused on the development and operation of gold and base metal projects in the Americas. The company's operating segments are its operating assets and include The Minosa Mine, the Apoena Mine, the Aranzazu Mine, the Almas Mine; and projects (Matupa, Tolda Fria, Borborema and Carajas Projects, and Corporate).
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.